Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LMF237 50 · 1 trial · 1 indication
HbA1c was performed on a blood sample obtained and measured by High performance liquid chromatography (HPLC). HPCL was performed at a central laboratory.
| Arm | Type | Description |
|---|---|---|
| LMF237 50/250 mg | EXPERIMENTAL | Patients took LMF237 50/250 mg twice daily for 14 weeks |
| LMF237 50/500 mg | EXPERIMENTAL | Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks |
| Placebo | PLACEBO_COMPARATOR | Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks |
| Name | Type | Description |
|---|---|---|
| LMF237 50/250 mg | DRUG | Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily |
| LMF237 50/500 mg | DRUG | Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily |
| Placebo | DRUG | Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily |
Inclusion Criteria: * Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy * HbA1c in the range of 7.0-10.0% * Body mass index in the range of 20-35 kg/m\^2 Exclusion Criteria: * Type 1 diabetes, monogenic diabetes, diabetes resulting from pancr...
LMF237 50 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus (T2DM). It is intended for patients whose diabetes is inadequately controlled with vildagliptin monotherapy. The drug is in Phase 3 clinical development and is not yet approved by regulatory authorities.
LMF237 50 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 3 clinical trials for Type 2 Diabetes Mellitus, though it remains investigational and has not been approved for commercial use.
LMF237 50 is in Phase 3 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not received regulatory approval. The Phase 3 trial has been completed, but the drug is still considered investigational until it is approved by health authorities.
LMF237 50 has one completed Phase 3 clinical trial, identified as NCT01811485. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of LMF237 in 171 patients with Type 2 Diabetes Mellitus inadequately controlled with vildagliptin monotherapy. The trial was conducted in Japan and enrolled adults aged 20 years and older.
No, LMF237 50 is not the same as vildagliptin. Vildagliptin is an existing diabetes medication used as monotherapy, while LMF237 50 is an investigational drug being studied as an add-on treatment for patients whose diabetes is not adequately controlled with vildagliptin alone. LMF237 50 is in Phase 3 clinical development.